Research Trials

If you have any questions or are interested in participating in one of our clinical research studies, please call us at 402.955.2691 or email us at clinicaltrials@nebraskacancer.com.

  • Cancer Type:

  • Biomarker:

  • Phase:

  • Keyword:

  • RMC-LUNG-101

    (Subprotocol C) A Platform Study of RAS(ON) Inhibitor Combinations in Patients With RAS-Mutated Non-Small Cell Lung Cancer (NSCLC)

    Cancer Type: Lung NSCLC

    Biomarkers: RAS G12D-mutated

    Phase: 1b/2

  • CTX-10726

    A Phase 1, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of CTX-10726 in Patients with Advanced Malignancies

    Cancer Type: Solid tumor

    Lines of Therapy: 2

    Biomarkers: PD-1, VEGF

    Phase: 1

  • Tempus: Gemini TP-CA-004 (NSCLC - Surveillance)

    Tempus NSCLC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With NSCLC Using NGS Assays

    Cancer Type: Lung NSCLC

    Phase: Observational

    View Details on ClinicalTrials.gov

  • SynDevRx, SDX-0103

    Phase 1b/2 study assessing the safety/efficacy of evexomostat (SDX-7320) in combination with the PI3Ka inhibitor Alpelisib (PIQRAY) plus fulvestrant in postmenopausal women at risk for hyperglycemia with advanced breast cancer and a PIK3CA mutation who have progressed on or following endocrine therapy plus a CDK4/6 inhibitor

    Cancer Type: BREAST

    Phase: 1,2

    View Details on ClinicalTrials.gov

  • TCMCB07-01

    Optimizing Body Mass Index (BMI) with TCMCB07 in Patients with Newly Diagnosed Metastatic Colorectal Cancer Undergoing Chemotherapy

    Cancer Type: Colorectal

    Lines of Therapy: 1

    Phase: 2

    View Details on ClinicalTrials.gov

  • WO45654

    A Phase III, Multicenter, Randomized, Double-blined, Placebo-controlled study evaluation the efficacy and safety of Inavolisib plus a CKD4/6 inhibitor and Letrozole vs Placebo plus CDK4/6 Inhibitor and Letrozole in patients with Endocrine Sensitive PIK3CA-Mutated, Hormone Receptor +, Her 2 -, Advanced Breast Cancer

    Cancer Type: BREAST

    Lines of Therapy: 1

    Biomarkers: PIK3CA

    Phase: 3

    View Details on ClinicalTrials.gov

  • TTX-080-001

    A Phase 1b Dose Expansion Study of TTX-080, an HLA-G Antagonist, as monotherapy and in combination with Pembrolizumab, Cetuximab or FOLFIRI plus Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies

    Cancer Type: Colorectal

    Lines of Therapy: 3, 2

    Phase: 1b

    View Details on ClinicalTrials.gov

  • VMT01-T101

    Phase 1/2a, First-in-human, Multicenter Dose Escalation and Dose Expansion Study of [203/212Pb] VMT01 Recepto-targeted, Image-guided Alpha-particle Therapy in Patients with Previously Treated unresectable or metastatic Melanoma

    Cancer Type: MELANOMA, Theranostics

    Lines of Therapy: 3, 2

    Phase: 1/2a

    View Details on ClinicalTrials.gov

  • Tempus: Gemini TP-CA-002 (CRC - Surveillance)

    Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients with CRC using NGS Assays

    Cancer Type: Colorectal

    Phase: Observational

    View Details on ClinicalTrials.gov

  • TER-2013-C01

    A Phase 1/2 Trial of TER-2013 in Patients with Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

    Cancer Type: Solid tumor

    Biomarkers: AKT, PI3K, PTEN

    Phase: 1

Purpose   •   Innovation   •   Relationship   •   Excellence

#caringforthegoodlife

© 2026 Nebraska Cancer Specialists  •  Privacy Policy  •  design by Chip Thompson

Meet DOT.
Skip to content